Introduction
The Fibroblast Growth Factor (FGF) family consists of at least 18 structurally related proteins involved in various physiological and pathological processes. These processes include cell growth, differentiation, angiogenesis, wound healing, and tumorigenesis. FGFs exert their biological effects by binding to and activating type I transmembrane tyrosine kinase receptors. Upon ligand binding, these receptors dimerize and autophosphorylate. Four distinct genes encode closely related FGF receptors: FGFR-1, -2, -3, and -4. Alternative splicing of mRNAs generates multiple forms of FGFR-1 to -3. A common splicing event in FGFR-1 and -2 produces receptors containing all three immunoglobulin-like domains (Ig domains) termed the alpha isoform. Alternatively, receptors containing only IgII and IgIII are termed the beta isoform. Only the alpha isoform has been identified for FGFR-3 and FGFR-4. Further splicing events for FGFR-1 to -3 involve the C-terminal half of the IgIII domain. These events result in FGF receptors with alternative IgIII domains (IIIb and IIIc) generated by two mutually exclusive alternative exons. A secreted FGF binding protein, the IIIa isoform, containing only the N-terminal half of the IgIII domain and some intron sequences, has also been reported for FGFR-1. Notably, mutations in FGFR-1 to -3 have been identified in patients with birth defects involving craniosynostosis.
Description
Soluble FGFR-1a (IIIc) Fc Chimera Human Recombinant, incorporating a Xa cleavage site and the Fc domain of human IgG1, is produced in a baculovirus expression system. This chimeric protein is a heterodimeric, glycosylated polypeptide chain comprising 601 amino acids with a molecular weight of 170 kDa. The purification of FGFR1 is achieved using proprietary chromatographic methods.
Physical Appearance
Sterile Filtered White lyophilized powder.
Formulation
CD331 was lyophilized from a sterile solution at a concentration of 1 mg/ml in 1xPBS.
Solubility
To reconstitute the lyophilized bFGF-R, it is recommended to dissolve it in sterile PBS at a minimum concentration of 100 µg/ml. The reconstituted solution can be further diluted in other aqueous solutions as needed.
Stability
Lyophilized FGFR1A can be stored at room temperature for up to 3 weeks; however, for extended storage, it is recommended to store it desiccated at a temperature below -18°C. After reconstitution, FGFR1 should be stored at 4°C for a period of 2-7 days. For long-term storage, it is advisable to store it below -18°C. To ensure optimal stability during long-term storage, the addition of a carrier protein (0.1% HSA or BSA) is recommended. Repeated freeze-thaw cycles should be avoided.
Purity
The purity of this product is greater than 90.0% as determined by SDS-PAGE analysis.
Biological Activity
The biological activity of this product is determined based on its ability to inhibit human FGF acidic-dependent proliferation in R1 cells. The ED50 for this inhibitory effect is typically in the range of 15.0-30.0 ng/ml.
Synonyms
FGFR-1, bFGF-R, C-FGR, CD331, fms-related tyrosine kinase 2, Pfeiffer syndrome, CEK, FLG, FLT2, KAL2, BFGFR, FGFBR, HBGFR, FGFR1/FGFR1OP2 FUSION GENE, FGFR1/ZNF198 FUSION GENE, FLG FGFR1/BCR FUSION GENE, FLG protein, FMS-LIKE GENE, N-sam tyrosine kinase, basic fibroblast growth factor receptor 1.
Amino Acid Sequence
RPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQL AESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSS EDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFK CPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYT CIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYS DPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSF EDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEDPRRASIEG RGDPEEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK